Bionano Genomics, Inc.: diluted earnings per share

What this measure means

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Exact concept: us-gaap:EarningsPerShareDiluted. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2021-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.

Reading these values

This selected numerical history matches Basic earnings per share for the same reporting intervals and original units. The accounting definitions remain distinct. Equal values do not establish that the concepts are interchangeable or explain why they match; filing dates and accessions may differ. Compare the definitions and source filings before combining them.

Context from the filing

Bionano Genomics' 2024 and 2025 statements display full dollar amounts and share counts rounded to the nearest thousand; the shares are not shown in thousand-share units and are not exact unrounded counts. The filing retrospectively reflects the one-for-60 reverse split filed January 24, 2025. It attributes equal basic and diluted shares to net losses and excludes potentially dilutive debentures, warrants, RSUs, PSUs and options. Excluded securities are not added to the reported weighted-average denominator. Read the source filing.

Selected filing history

Related financial histories

• Bionano Genomics, Inc.: total assets
• Bionano Genomics, Inc.: total liabilities
• Bionano Genomics, Inc.: stockholders equity
• Bionano Genomics, Inc.: cash and cash equivalents
• Bionano Genomics, Inc.: net income or loss
• Bionano Genomics, Inc.: operating cash flow
• Bionano Genomics, Inc.: capital expenditure payments
• Bionano Genomics, Inc.: contract revenue excluding tax
• Bionano Genomics, Inc.: financing cash flow
• Bionano Genomics, Inc.: investing cash flow
• Bionano Genomics, Inc.: retained earnings or deficit
• Bionano Genomics, Inc.: basic weighted-average shares
• Bionano Genomics, Inc.: diluted weighted-average shares
• Bionano Genomics, Inc.: basic earnings per share
• Bionano Genomics, Inc.: income tax expense or benefit
• Bionano Genomics, Inc.: net property, plant and equipment
• Bionano Genomics, Inc.: share-based compensation expense
• Bionano Genomics, Inc.: operating income or loss
• Bionano Genomics, Inc.: current assets
• Bionano Genomics, Inc.: interest expense
• Bionano Genomics, Inc.: current liabilities
• Bionano Genomics, Inc.: current accounts payable
• Bionano Genomics, Inc.: goodwill carrying amount
• Bionano Genomics, Inc.: net finite-lived intangible assets
• Bionano Genomics, Inc.: net current accounts receivable
• Bionano Genomics, Inc.: net inventory
• Bionano Genomics, Inc.: selling, general and administrative expense
• Bionano Genomics, Inc.: research and development expense

Inspect the source

Entity

Bionano Genomics, Inc. / CIK 0001411690

Captured

2026-09-20T08:01:58.297Z

SEC response SHA-256

de1f7683e64ca05fd1e6239a8009bb07a28d93e0115f74423aec0ba56b765b33

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001411690.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))